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Perceived dyscognition or fibrofog has been ranked as one 
major contributor of distress in fibromyalgia (FM). The 
Multidimensional Inventory of Subjective Cognitive 
Impairment (MISCI) was devised as a brief and comprehen-
sive self- report measure of cognitive function in FM. The 
main objective of the present study was to assess the psy-
chometric properties of the Spanish version of the MISCI. 
One hundred and twenty patients with FM were included, 
and dimensionality, reliability, and validity of the MISCI 
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1  | INTRODUC TION
Fibromyalgia (FM) is a syndrome characterized by a broad range of symptoms such as chronic widespread musculoskel-
etal pain, fatigue, stiffness, sleep problems, psychological distress (depression and anxiety) and cognitive disturbances 
(Häuser et al., 2015). Indeed, over 50% of patients with FM present a subjective perception of impaired cognitive abil-
ities (Katz, Heard, Mills, & Leavitt, 2004) and this has been ranked as one of the top five major contributors to distress 
in FM (Bennett, Jones, Turk, Russell, & Matallana, 2007), associated with negative impact on health- related quality of 
life, perceived disability (Arnold et al., 2008), impaired job performance, and increased health- care utilization (Wilson, 
Robinson, & Turk, 2009). Perceived dyscognition involves complaints about memory, concentration, verbal expres-
sion, activity management and scheduling, mental agility, and generally experiencing life through a haze (Arnold et al., 
2008). Altogether, these cognitive complaints have been popularly termed fibrofog (from fibromyalgia and brain- fog).
Although pain has been the main focus of research and clinical care in FM, more recently, fibrofog has been 
proposed as a core domain for FM assessment in randomized controlled trials and clinical practice (Mease et al., 
2009), and is one component of the current diagnostic criteria for FM (Wolfe et al., 2010). Research has shown 
that perceived dyscognition is related to objective cognitive impairments in memory, verbal fluency, attention/
concentration and executive functioning (Kravitz & Katz, 2015; Park, Glass, Minear, & Crofford, 2001; Tesio et al., 
2015). However, in addition to objective cognitive difficulties, other contributing factors, such as emotional dis-
tress, have demonstrated appreciable effects on fibrofog (Ambrose, Gracely, & Glass, 2012; Gelonch, Garolera, 
Valls, Rosselló, & Pifarré, 2016; Glass, Park, Minear, & Crofford, 2005). Core FM symptoms such as fatigue, unre-
freshing sleep and mood alterations may contribute to fibrofog (Williams, Clauw, & Glass, 2011). Although some 
authors reported normal results on neuropsychological tests in persons with FM, methodological limitations of 
the research so far (e.g., narrow range of cognitive domains, small sample size, poor ecological validity of tests) 
may also call into question the findings regarding normality of objective cognitive performance in patients with 
FM (Ambrose et al., 2012).
Perceived cognitive disturbances are not only reported by people with FM but also by patients with other 
chronic pain conditions and mood and anxiety disorders (American Psychiatric Association, 2013; Iverson & 
were evaluated. Data from brain imaging (N = 61) were 
also used in validity analyses. Known- groups validity was 
evaluated by including a subset of 45 patients without FM 
in partial/total remission from depression. Sensitivity to 
change was assessed after a mindfulness- based interven-
tion. Spanish version of the MISCI exhibited a one- factor 
structure, excellent internal consistency, and good conver-
gent validity with symptomatology and gray matter vol-
umes in anterior and middle cingulate cortices. Significant 
improvements in MISCI scores after a mindfulness- based 
intervention were reported. An additive effect of FM and 
depression regarding MISCI scores was also observed. 
Self- reported depression, anxiety, and problems in balance 
predicted the 38% of the MISCI variance. The Spanish ver-
sion of the MISCI is a valuable instrument to include in FM 
research and clinical practice.
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McCracken, 1997). Perceived dyscognition may be indicative of truly impaired cognitive functioning or repre-
sent a patient’s perception of impairment where none exists. However, evidence shows that, irrespectively of 
real objective impairment, fibrofog can contribute to perceived functional impairment (McCracken & Iverson, 
2001; Pedrelli, Baer, Losifescu, & Fava, 2010; Saffer, Lanting, Koehle, Klonsky, & Iverson, 2015). Actually, around 
42% of patients with chronic pain report at least one cognitive complaint (Iverson & McCracken, 1997). Causal 
and maintaining mechanisms of objective and subjective cognitive impairment in FM are largely unknown. One 
hypothesis suggests that cognitive impairment in chronic pain may be due to the interference of pain in cognitive 
processes, since it could compete for attentional resources and so restrict available mental resources for cognitive 
tasks (Dick, Verrier, Harker, & Rashiq, 2008). Hypervigilance to pain and to pain- related information has already 
been extensively described in patients with FM (Häuser et al., 2015). In this regard, higher catastrophizing or 
pain- related fear/anxiety can be related to more difficulties in diverting attention away from a painful event, so 
limiting the available attentional resources (Roth, Geisser, Theisen- Goodvich, & Dixon, 2005). In previous studies 
in patients with chronic pain or FM, despite heterogeneous results, cognitive complaints have been linked to pain 
intensity, depression (Gelonch, Garolera, Valls, Rosselló, & Pifarré, 2017; McCracken & Iverson, 2001), anxiety, 
sleep problems, and fatigue (Kravitz & Katz, 2015). As proposed by Williams et al. (2011), perceived dyscognition 
in FM may be part of a “symptom cluster” (Dodd, Miaskowski, & Paul, 2001) with other FM symptoms, such as 
fatigue, sleep and mood disturbances (which are in turn commonly associated with many chronic illnesses), height-
ening respective intensity with their co- ocurrence. As one might expect, several studies have reported strong pos-
itive correlations between measures of cognitive impairment, and mood or fatigue in FM (Ambrose et al., 2012). 
Since both subjective and objective cognitive impairment have been widely reported in patients with depression 
(McIntyre et al., 2013) and depressive symptoms are very frequent in patients with FM (Häuser et al., 2015), 
cognitive complaints in FM are frequently attributed to depressive symptoms. Such neurobehavioral features 
may reflect disturbed centrally mediated processes in FM. In this regard, FM substantially overlaps with other 
syndromes characterized by impaired pain regulation of central origin, such as irritable bowel syndrome, chronic 
fatigue syndrome, temporomandibular joint disorder or vulvodynia syndrome, which are classed together under 
the Central Sensitivity Syndromes (CSS) umbrella (Woolf, 2011; Yunus, 2007). Thus, objective and subjective cog-
nitive problems, even after excluding correlates with other symptoms as contributing factors, may be indicative 
of real alterations at the brain level (Ceko, Bushnell, & Gracely, 2012). In this regard, accelerated brain gray matter 
loss has been reported in FM suggesting premature aging in this disorder (Kuchinad et al., 2007). In fact, a pattern 
of local abnormalities of gray matter (i.e., reductions or increments) involving areas related to pain processing, 
stress response, and cognitive control have been described in patients with FM (Wallit, et al., 2016). However, it is 
not yet clear whether these alterations may be causative or just an epiphenomenon of FM.
Although current recommendations indicate the need to include fibrofog as an outcome in FM clinical research 
(e.g., Mease et al., 2009), most studies do not assess fibrofog as a variable of interest. Consequently, very little is 
known about the impact of available treatments for fibrofog in FM. In a recent network, meta- analysis focusing 
on pain and quality of life, small effects of questionable clinical relevance for some pharmacological treatments 
(i.e., pregabalin, SNRIs) and more ubiquitous effects of small- moderate magnitude for nonpharmacological pro-
grams (such as multicomponent therapy, aerobic exercise and cognitive- behavior therapy) were reported (Nüesch, 
Häuser, Bernardy, Barth, & Jüni, 2013). Further studies should test whether these interventions are also effective 
in reducing fibrofog. A promising intervention (Adler- Neal & Zeidan, 2017) for targeting fibrofog and other core 
symptoms in FM is Mindfulness- Based Stress Reduction (MBSR; Kabat- Zinn, 1990). Mindfulness training has been 
related to ameliorations of FM symptoms in previous studies (see Lauche, Cramer, Dobos, Langhorst, & Schmidt, 
2013 for a review) and also to improvements in cognitive function (Chiesa, Calati, & Serretti, 2011; Lao, Kissane, 
& Meadows, 2016).
Examination of fibrofog in clinical research may be hindered by the fact that most instruments for assessing 
cognitive dysfunction are very lengthy, non- FM specific, and do not evaluate all domains of perceived cognitive 
impairment in FM (such as the Multiple Abilities Self-report Questionnaire or MASQ; Seidenberg, Haltiner, Taylor, 
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Hermann, & Wyler, 1994). In response to these limitations, the Multidimensional Inventory of Subjective Cognitive 
Impairment (MISCI; Kratz, Schilling, Goesling, & Williams, 2015) was devised to be a brief yet comprehensive self- 
report measure of multifaceted cognitive functioning for use in both clinical and research practice.
The MISCI is a 10- item patient- reported instrument aimed at assessing the construct of perceived cognitive 
function in patients with FM and is composed of a selection of the most informative items from the cognitive 
functioning item banks of the Patient- Reported Outcomes Measurement Information System and the Quality 
of Life in Neurological Disorders initiatives (PROMIS®/NQ; Cella et al., 2010). This inventory covers five main 
clinically relevant cognitive functioning domains: (1) memory, (2) verbal language ability, (3) general mental 
clarity, (4) attention/concentration, and (5) executive functioning. To develop this instrument, factorial analyses 
were completed and Item Response Theory analyses were performed to identify the two most discriminating 
items for each clinically relevant cognitive domain. The original English version of the MISCI showed excellent 
internal consistency, low ceiling/floor effects, and good convergent validity with FM impact severity and the 
MASQ (Seidenberg et al., 1994) a classical (and longer) measure of perceived cognitive abilities which evaluates 
non- FM- specific domains such as language, verbal memory, attention, visual perceptual, and visual memory 
(Kratz et al., 2015).
The main objective of the present study was to assess the psychometric properties of the Spanish version of 
the MISCI in a sample of patients with FM. Specifically, we evaluated the dimensionality, internal consistency, 
test–retest reliability, construct (convergent and known- groups) validity, and sensitivity to change in this instru-
ment. Structural neuroimaging measurements were also used to evaluate the convergence between MISCI scores 
and brain- derived objective data. To our knowledge, this is the first study that surveyed the psychometric prop-
erties of a non- English version of the MISCI outside the United States. Given the well- known contributive effect 
of depressive symptoms on fibrofog reported by many authors (e.g. Gelonch et al., 2017), known- groups validity 
of the MISCI and the putative additive effect of depression on fibrofog were tested by comparing MISCI scores 
in three clinical samples: (1) Patients with FM without depression, (2) with FM and comorbid depression, and (3) 
patients without FM reporting residual depressive symptoms. Sensitivity to change in the MISCI was also assessed 
after a MBSR program using early- stage data from the EUDAIMON study, a randomized controlled trial (RCT) 
examining the cost- effectiveness of mindfulness- based stress reduction in patients with FM (Feliu- Soler et al., 
2016). Finally, in order to test for potential symptom cluster contributors to fibrofog, a hierarchical regression 
analysis was performed with core FM symptoms as predictors of MISCI scores.
2  | METHODS
2.1 | Participants
The FM study sample was composed of 120 adult patients with a FM diagnosis according to American College 
of Rheumatology (ACR) 1990 criteria (98.3% women, mean age = 53.8 years, SD = 6.9, range = 36−65 years) re-
cruited at the Rheumatology service of Sant Joan de Déu Hospital (St. Boi de Llobregat, Spain). MISCI was admin-
istered (together with the other paper- and- pencil measures) as part of the evaluation protocol of the EUDAIMON 
study (Feliu- Soler et al., 2016). All recruited patients in this study were selected following a multistage recruit-
ment process. A health psychologist screened potential participants through a phone interview and then made 
an appointment for those patients that met inclusion/exclusion criteria and agreed to participate in the study. 
Face- to- face interviews were performed once written consent had been obtained. A detailed description of the 
study protocol can be found elsewhere (Feliu- Soler et al., 2016). The following inclusion/exclusion criteria were 
applied: Patients of both genders between 18 and 65 years, provision of written informed consent to participate, 
able to understand and read Spanish, not participating in other studies, not receiving psychological treatment 
during the last 12 months, not reporting previous mindfulness training, neither having comorbidity (according 
to their hospital medical record) with severe medical illness, psychotic symptoms, or substance abuse, nor being 
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involved in ongoing litigation relating to FM. The sample size of 120 patients available for psychometric analyses 
of the MISCI was considered appropriate to validate the MISCI since the classic criteria of ≥10 cases per item was 
met (Kass & Tinsley, 1979). Nearly half of these patients (n = 56) presented current comorbid Major Depressive 
Disorder (64 did not present) according to the Structured Clinical Interview for DSM Axis I Disorders (SCID- I; First, 
Spitzer, Gibbon, & Williams, 1997) administered by a health psychologist. Additionally, to test the known- groups 
validity of the MISCI, a sample of 45 non- FM adult primary care patients (83.7% women, mean age = 52.2 years, 
SD = 17.2, range = 23−87 years) in partial/total remission from Major Depressive Disorder according to clinical 
records (Residual Depressive Symptomatology group, RDS) were also invited to complete the MISCI. See Table 1 
for more detailed information. This last sample was participating in a 12- month nonrandomized controlled trial 
on the cost- effectiveness of active monitoring (vs. stand- alone antidepressant treatment) in mild- moderate major 
depression (the INFAP study, Rubio- Valera et al., 2015). Signed informed consent was obtained from all patients 
before initiating their participation in the study and the EUDAIMON and INFAP study protocols were approved by 
the Clinical Research Ethics Committee at the Sant Joan de Déu Foundation (CEIC reference numbers: PIC- 33- 11 
and EPA- 24- 12).
2.2 | Procedure
Items corresponding to the 10- item original MISCI instrument were drawn from the NIH PROMIS®/Neuro- QOL 
item banks, which underwent a rigorous forward and back- translation procedure (English–Spanish–English) with 
multiple expert reviews and cognitive debriefing with a sample of native Spanish speakers (Eremenco, Cella, & 
Arnold, 2005). As stated above, a paper- and- pencil version of the MISCI and sociodemographic data were com-
pleted by all the patients as part of the EUDAIMON and INFAP studies. To evaluate the construct validity of 
the MISCI, a subsample of 96 patients with FM also completed a battery of self- report measures. Additionally, 
to extend the evaluation of construct validity of the MISCI with brain- based objective variables, anatomic brain 
measurements from 61 patients were obtained and gray matter volumes of specific regions of interest poten-
tially related to fibromyalgia (Lin, Lee, & Weng, 2016; Wallit, Ceko, Gracely & Gracely, 2016) were calculated. 
To evaluate MISCI sensitivity to change, 59 patients from the EUDAIMON study (37 allocated to MBSR and 
22 to Treatment- as- usual [TAU]) also completed the MISCI pre- and postintervention (8 weeks). MBSR is an 8- 
week program which includes meditative training (e.g., body- scan, breath focusing, walking meditation, or mind-
ful eating), mindful stretches, and psycho- educative content aimed at increasing more adaptive responses in the 
context of stress, pain, and illness (Adler- Neal & Zeidan, 2017; Kabat- Zinn, 1990). Since little clinical change has 
been reported in patients allocated to TAU in other RCTs with similar samples and equivalent measurement time 
frames (e.g., Luciano et al., 2011), pre–post data from the 22 patients allocated to TAU was also used to test the 
temporal stability of the MISCI. TAU, as it is commonly provided in Spanish health- care settings, mainly consists 
of pharmacological treatment adjusted to the symptomatic profile of the patients and counseling on aerobic ex-
ercise adjusted to patients’ physical limitations is usually provided. Participants from the INFAP study also com-
pleted a paper- and- pencil version of the MISCI. The Patient Health Questionnaire (PHQ- 9, Kroenke & Spitzer, 
2002) was only used in this last sample to describe severity of depressive symptoms. All data were obtained in 
accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its subsequent updates. 
The FSJD Research Committee Board evaluated and approved both study protocols (PIC- 102- 15 and EPA- 24- 12, 
respectively).
2.3 | Study measures
All study participants completed a sociodemographic and clinical questionnaire with gender, date of birth, marital 
status, educational level, employment status, and years with FM (when applicable).
The following measures, including the MISCI, were administered in the FM sample:
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TABLE  1 Characteristics of the study samples (i.e., FM with and without depression groups and sample with 
residual depressive symptoms and FM negative)
Socio- demographic 
variables
FM Total 
(n = 120)
FM 
 (n = 64)
FM + MDD 
 (n = 56)
RDS 
 (n = 45) p*
Gender, n females (%) 118 (98.33) 62 (96.87) 56 (100.00) 36 (80.00) 0.001
Age, M (SD) 53.79 (6.88) 53.06 (7.07) 54.67 (6.60) 52.19 (17.16) n.s.
Years of schooling, M (SD) 9.78 (2.45) 10.22 (2.23) 9.29 (2.63) 9.16 (4.17) n.s.
Living with (spouse/
partner/relatives), n (%)
117 (97.50) 63 (98.44) 54 (96.43) 40 (88.89) n.s.
Marital status, n (%) n.s.
 Single 6 (5.00) 2 (3.12) 4 (7. 14) 2 (4.44) –
 Married/Living with a 
partner
92 (76.67) 52 (81.25) 40 (71.43) 38 (83.44) –
 Separated/divorced 16 (13.33) 8 (12.50) 8 (14.29) 4 (8.89) –
 Widowed 6 (5.00) 2 (3.12) 4 (7.14) 1 (2.22) –
Work status, n (%) n.s.
 Homemaker 13 (10.83) 7 (10.94) 6 (10.71) 4 (8.89) –
 Paid employment 41 (34.17) 25 (39.06) 16 (28.57) 19 (42.22) –
 Paid employment but on 
sick leave
8 (6.67) 4 (6.25) 4 (7.14) 7 (15.56) –
 Unemployed with 
allowance
7 (5.83) 7 (10.93) 0 (0.00) 3 (6.67) –
 Unemployed without 
allowance
23 (19.17) 12 (18.75) 11 (19.64) 3 (6.67)
 Retired/pensioner 14 (11.67) 7 (10.93) 7 (12.50) 8 (17.78) –
 Temporally disabled 3 (2.50) 0 (0.00) 3 (5.35) 0 (0.00) –
 Others (e.g., student) 11 (9.16) 2 (3.12) 0 (0.00) 1 (2.22) –
Clinical variables, M (SD) –
 Years with FM 11.77 (8.11) 10.80 (7.18) 12.89 (8.99) – –
 FIQR- Total (0–100) 61.12 (20.11) 51.03 (18.95) 72.29 (14.84) – –
 Function (0–30) 18.43 (6.14) 16.45 (5.69) 20.62 (5.92) – –
 Overall impact (0–20) 10.29 (7.17) 7.06 (6.96) 13.98 (5.46) – –
 Severity of symptoms 
(0–50)
32.41 (9.22) 27.79 (9.06) 37.69 (6.05) – –
 FSDC- Total (0–31) 22.38 (5.13) 20.82 (5.44) 24.27 (4.04) – –
 FSDC- WPI (0–19) 13.73 (3.64) 13.12 (3.87) 14.43 (3.25) – –
 FSDC- SSS (0–12) 8.64 (2.42) 7.68 (2.39) 9.81 (1.91) – –
 HADS- Total (0–42) 18.41 (8.43) 14.11 (7.02) 23.25 (7.20) – –
 HADS- A (0–21) 10.80 (4.50) 9.22 (4.18) 12.57 (4.20) – –
 HADS- D (0–21) 7.61 (5.12) 4.92 (4.13) 10.68 (4.38) – –
 PSS (0–40) 21.71 (9.31) 17.69 (9.11) 26.38 (7.17) – –
 PCS- Total (0–52) 22.03 (13.16) 18.70 (13.39) 25.93 (11.86) – –
 PCS- Rumination (0–16) 7.39 (4.93) 6.42 (5.06) 8.53 (4.55) – –
(Continues)
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1. The Multidimensional Inventory of Subjective Cognitive Impairment (MISCI; Kratz et al., 2015) is a 10-item 
instrument with a 5-point Likert scale (from 1 “Not at all/Never” to 5 “Very much/Always”) to evaluate 
subjective cognitive function in patients with FM. It is composed of six positively worded items reflecting 
perceived cognitive abilities (e.g., “I have been able to think clearly without extra effort”) and four negatively 
worded items for perceived cognitive difficulties (e.g., “I had trouble planning out the steps of a task”), 
including items for the following cognitive domains (two per domain): mental clarity, memory, attention/
concentration, executive functioning, and language. The time frame is “the past 7 days.” The four nega-
tively worded items from the MISCI were reverse scored. Items were summed so that higher total scores 
(ranging from 10 to 50) are indicative of better subjective cognitive functioning.
2. The Revised Fibromyalgia Impact Questionnaire (FIQR; Bennett et al., 2009; Luciano, Aguado, Serrano-Blanco, 
Calandre, & Rodriguez-Lopez, 2013) is a primary efficacy endpoint measure in FM clinical trials and is the “gold 
standard” assessment measure for multidimensional functional status in patients with FM. It includes 21 items 
rated on an 11-point Likert scale (from 0 to 10), with higher scores reflecting greater impairment. FIQR items are 
distributed into three domains: “physical function” (9 items); “overall impact” (2 items); and “severity of symp-
toms” (10 items). A total score for the FIQR (from 0, minimum impact, to 100, maximum impact) can be calcu-
lated by dividing the physical function subscore by 3 and the severity of symptoms domain by 2 and then 
summing both values to the overall impact subscore (unchanged). Cronbach’s α of the FIQR in our sample was 
excellent (α = .92). The sixth item from the “severity of symptoms” section (i.e., 3f item) is related to fibrofog: 
“Please rate your level of memory problems” (ratings range from 0, good memory, to 10, very poor memory). 
This item has been also used in the present study as a variable of perceived cognitive impairment.
3. Fibromyalgia Survey Diagnostic Criteria (FSDC; Carrillo-de-la-Peña et al., 2015; Häuser et al., 2012): A 6-item self-
administered questionnaire aimed at evaluating key symptoms of FM according to the latest ACR revision. FSDC 
includes two domains: (1) the Widespread Pain Index (WPI) identifying 19 body areas where pain/tenderness 
was felt during the previous week (with scores ranging from 0 to 19), and (2) the Symptom Severity Scale (SSS; 
with scores ranging from 0−12) composed of three items on major FM symptoms (i.e., fatigue, trouble thinking/
remembering, and waking up tired or unrefreshed) scored from 0 = no problem to 3 = severe, continuous, life-
disturbing problems, and three additional items on other somatic complaints (i.e., pain/cramps in lower abdo-
men, depression, and headache) coded as present = 1 or absent = 0. A total score of fibromyalginess ranging 
from 0 to 31 can also be obtained by summing the WPI and the SSS scale. Cronbach’s α of the SSS subscale in 
our sample was considered to be adequate (α = .66). The item on the presence of cognitive symptoms (i.e., at-
tention, concentration or memory problems) from the SSS (ranging from 0 = “No problem” to 3 = “Severe: per-
vasive, continuous, life-disturbing problems”) was also studied separately as an additional convergent measure 
of perceived cognitive impairment.
Socio- demographic 
variables
FM Total 
(n = 120)
FM 
 (n = 64)
FM + MDD 
 (n = 56)
RDS 
 (n = 45) p*
 PCS- Magnification (0–12) 4.59 (3.07) 4.14 (3.14) 5.11 (2.92) – –
 PCS- Helplessness (0–24) 10.01 (6.35) 8.05 (6.12) 12.29 (5.87) – –
 PHQ- 9 (0–27) – – – 9.03 (6.71) –
Notes. FIQR, Fibromyalgia Impact Questionnaire Revised; FSDC, Fibromyalgia Survey Diagnostic Criteria questionnaire 
– WPI, Widespread Pain Index; SSS, Symptom Severity Scale; FM, Fibromyalgia; HADS, Hospital Anxiety and Depression 
Scale; MDD, Major Depressive Disorder; PCS, Pain Catastrophizing Scale; PHQ- 9, Patient Health Questionnaire; PSS, 
Perceived Stress Scale; RDS, Sample with Residual Depressive Symptomatology without a FM diagnosis.
*T- tests were used to explore differences in continuous measures between FM total sample and the RDS group; χ2 was 
used for categorical variables.
TABLE  1  (Continued)
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4. The Hospital Anxiety and Depression Scale (HADS; Luciano, Barrada, Aguado, Osma, & García-Campayo, 2014; 
Zigmond & Snaith, 1983): Originally developed to assess anxiety and depressive symptom severity in nonpsy-
chiatric hospital patients and includes 14 items on a 4-point Likert scale (from 0 = not at all to 3 = very often) in 
two subscales: HADS-A: Anxiety and HADS-D: Depression. Possible scores range from 0 to 21 for both anxiety 
and depressive subscales, with higher scores suggesting greater severity. Cronbach’s αs of the HADS-A and 
HADS-D subscales in our sample were good (.87 and .86, respectively).
5. The Perceived Stress Scale (PSS-10; Cohen & Williamson, 1988; Remor, 2006): IA 10-item self-administered 
5-point Likert scale (from 0 = Never to 4 = Very often) instrument to assess the degree to which situations in 
one’s life are considered stressful in the previous month. Scores range from 0 to 40. Cronbach’s α of the PSS in 
our sample was considered to be excellent (α = .91).
6. The Pain Catastrophizing Scale (PCS; García-Campayo et al., 2008; Sullivan, Bishop, & Pivik, 1995) is a 13-item 
instrument using a 5-point Likert scale (0 = not at all to 4 = all the time) that evaluates three cognitive dimen-
sions related to pain catastrophizing: Rumination (4 items) or the inclination to focus excessively on pain sensa-
tions, Magnification (3 items) understood as the tendency to amplify the threat value of pain sensations and, 
finally, Helplessness (6 items), the inclination to perceive oneself as unable to control the intensity of pain; a PCS 
total score (score range between 0−52) and three subscale scores (with scores ranging from 0−16, 0−12, and 
0−24, respectively) can be computed through the algebraic sum of ratings, with higher scores indicating greater 
pain catastrophizing. The internal consistency of the PCS was excellent in our FM sample (Cronbach’s α = .94).
7. The Structured Clinical Interview for DSM Axis I Disorders (SCID-I; First et al., 1997) was used to diagnose current 
Major Depressive Episode in the FM sample.
8. Structural neuroimaging data were collected on a Philips Ingenia 3.0 T whole body system equipped with a 12-ele-
ment receive-only head matrix coil. High-resolution anatomical T1-weighted scans were obtained using a magnetiza-
tion-prepared rapid acquisition gradient echo (MPRAGE) sequence with the following scanning parameters: repetition 
time (TR) = 9 ms, echo time (TE) = 4 ms, inversion time = 1,000 ms, flip angle = 8°, field of view 
(FOV) = 240 × 240 × 170 mm, matrix size = 240 × 240, number of slices = 170, and acceleration factor (SENSE) = 2 
with an isotropic resolution of 1 × 1 × 1 mm3. All images were analyzed with SPM12 (Wellcome Department of 
Imaging Neuroscience, London; http://www.fil.ion.ucl.ac.uk/spm/software/spm12) running under MATLAB (Release 
2012b; The MathWorks, Inc., Natick, MA, USA). Gray matter, white matter and cerebrospinal fluid were segmented 
from the T1 images of the participants employing the CAT toolbox (http://www.neuro.uni-jena.de/cat) for SPM12. 
The following specific gray matter regions were selected in accordance with a recent review and meta-analysis (Lin 
et al., 2016; Walitt et al., 2016): prefrontal cortex, orbitofrontal cortex, cingulate cortex, insula, precuneus, superior 
temporal gyrus, cerebellum, brain stem, and subcortical structures. Volumes for the regions of interest were auto-
matically calculated according to the Neuromorphometrics atlas (http://www.neuromorphometrics.com). Total brain 
volume was obtained by summing the volumes of the gray matter, white matter, and cerebrospinal fluid segments.
2.4 | Data analyses
Sociodemographic information and available clinical characteristics were reported with descriptive statistics of 
frequencies, means, and standard deviations (SD). T- tests and χ2 were used to test for differences between FM 
total sample and the sample without FM with Residual Depressive Symptomatology (RDS) in sociodemographic 
data. All data were analyzed with SPSS v22.0 and Mplus v7.2.
2.4.1 | Dimensionality
Data from the full FM sample (N = 120) were used to test the factor structure in a Confirmatory Factorial Analysis 
(CFA) with all MISCI items loading on one latent factor (Model 1). Since psychological instruments composed of 
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both positively and negatively formulated items tended to obtain worse fit for unidimensional models because 
positively phrased items are prone to load on one factor and negatively phrased items on another (Woods, 2006), 
a one- factor model with “method effects” (Model 2) as a respecification of Model 1 was also tested. Model 2 in-
corporated correlated error terms on the negatively phrased items of the MISCI (items 7, 8, 9, and 10). Therefore, 
six correlated residuals were specified. Moreover, items situated in a separate instrument section are likely to 
covary (Luciano et al., 2013). The maximum likelihood estimation with robust standard errors was applied to test 
the fit of the two alternative factor models and the following model fit indices were examined (the values in 
parentheses denote goodness- of- fit standards): the χ2 test (nonsignificant value), the Tucker–Lewis index, the 
comparative fit index (TLI and CFI ≥.95 indicate an acceptable fit, and ≥.97 indicate a good fit), and the root mean 
square error of approximation with 90% confidence intervals (RMSEA ≤.08 indicates an acceptable fit and ≤.05 
indicates a good fit).
2.4.2 | Internal consistency
Cronbach’s α coefficient was calculated in the FM sample with acceptable α values of .60 for exploratory research 
and of .70 for confirmatory research (Hair, Anderson, Tatham, & Black, 1998). Additionally, we assessed homoge-
neity of the MISCI by inspecting the corrected item- total correlation (correlation of the item designated with the 
summed score for all other subscale items). A common rule of thumb is that these values should be at least .30 
(Nunnally & Bernstein, 1994).
2.4.3 | Test–retest reliability
To determine the stability over time of the MISCI, test–retest reliability was explored using the Intraclass 
Correlation Coefficient (ICC; 2- way random, absolute agreement with 95% CI; Trevethan, 2017) using data from 
the TAU group (around 2 months elapsed between pre–post assessments). The common cut- off points for reli-
ability assessment are >.90 (excellent), .75−.90 (good), .60−.75 (moderate), and <.60 (low).
Convergent construct validity of the MISCI was studied by means of Pearson’s moment correlations between 
MISCI and clinical variables related to FM- related symptoms (FIQR, FSCD, HADS subscales, and PSS) and Pain 
Catastrophizing (PCS). Associations with FIQR item “memory problems” and the FSCD item “problems with atten-
tion, concentration or memory” were also evaluated as specific perceived cognitive impairment items. Since these 
specific items are considered “legacy measures” of fibrofog, high correlations are expected (r > .60). Pearson cor-
relations between MISCI scores and specific brain areas volumes were also evaluated. Effect size of correlations 
were interpreted in the light of the Ferguson (2009) paper where rs between .20 and .49 mean a minimum effect 
representing a “practically” significant effect for social science data, .50 to .79 correspond to a “moderate effect” 
and ≥.80 to a strong effect size. Since total brain volume, age, and years with FM may be theoretically related 
to specific brain area volumes, partial correlations controlling for these variables were also performed for those 
specific regions presenting significant zero- order correlations with MISCI.
Known- groups construct validity: The known- groups validity approach is founded on the basis that spe-
cific subgroups of patients might be expected to score differently from others. T- test comparisons were 
performed to assess the validity of the MISCI to discriminate among FM patients without depression (accord-
ing the SCID- I), patients with FM with depression, and patients without FM with residual depressive symp-
toms. We calculated between- groups effect sizes using Cohen’s d (rule of thumb for Cohen’s d: .20 = small, 
.50 = medium, and .80 = large effect sizes). As cognitive complaints are usually associated with depressive 
symptomatology, an additive effect of MDD and FM diagnosis on MISCI scores (i.e., lower scores) was ex-
pected to be found. In this regard, better results in the MISCI (i.e., higher scores) were expected in patients 
with FM without MDD and even better in those patients with residual depressive symptoms (without FM or 
current MDD diagnosis).
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2.4.4 | Sensitivity to change
To determine the usefulness of the MISCI as an outcome measure of interventions in FM, sensitivity to change was 
explored with repeated- measures ANOVA comparing patients allocated to MBSR and those whom received TAU. 
Partial eta squared (ηp
2) for group x time effect size calculation was used (interpreted as follows: .04−.24 = mini-
mum, .25−.63 = moderate, ≥.64 = strong effect sizes; Ferguson, 2009). Paired samples t- test and Cohen’s d 
correcting for dependence between means using Morris and DeShon’s (2002) equation were used for posthoc 
analyses. To evaluate the clinical effectiveness of the MBSR intervention, statistical significance, and effect size 
of changes in FIQR were evaluated.
Finally, to test for symptoms in FM which are potential contributors to perceived cognitive impairment, a hi-
erarchical multiple regression of MISCI scores using FIQR items for pain, energy/fatigue, stiffness, sleep quality, 
tenderness to touch, depression, anxiety, problems with balance, and environmental sensitivity as predictors was 
performed. This analysis was carried out controlling first (with stepwise method at p < .05) for sociodemographic 
variables (gender, age, and years of schooling) and medical data (i.e., years with FM, use of the following psycho-
tropic drugs: narcotic analgesics, benzodiazepines, antidepressants, hypnotics, anti- epileptics), and selected FIQR 
items as the second step (entry method).
3  | RESULTS
3.1 | Dimensionality
The χ2 value for both models was significant (model 1 = 157.093, p < .001; model 2 = 49.031, p < .001). The other 
fit indices of model 1 did not indicate adequate fit to the data (CFI = .79; TLI = .73 and RMSEA = .17, 90% CI: 
.14–.20). The inclusion of correlated residuals in model 2 substantially improved model fit (CFI = .97; TLI = .95 and 
RMSEA = .08 (90% CI: .04–.11). In addition, the four correlated residuals were statistically significant (θ7,8 = .49, 
θ7,9 = .36, θ7,10 = .25, θ8,9 = .51, θ8,10 = .43, θ9,10 = .67; all p < .05). Therefore, model 2 yielded support for the uni-
dimensional model of the MISCI when method effects were taken into account. All standardized factor loadings 
ranged from .53 to .87 in model 2 (lambda coefficients), were statistically significant (all p < .001) and in the fair to 
excellent range (Comrey, 1973). See Table 2 for standardized factor loading estimates.
3.2 | Reliability
Cronbach’s α coefficient was .91, indicating excellent internal consistency of the MISCI (Cicchetti, 1994). Removal 
of any of the MISCI items did not lead to a significant increase in the inventory’s α coefficient values and all cor-
rected item- total correlations were above the minimum cut- off of .30 recommended by Nunnally and Bernstein 
(1994), reflecting satisfactory scale homogeneity. For more details see Table 2. Intraclass correlation coefficient 
(ICC) was .88 (95% CI = .71–.95) suggesting good test–retest reliability for the MISCI (Portney & Watkins, 1993).
3.3 | Convergent validity
As expected, significant negative correlations (all p < .01) with moderate effect size (Ferguson, 2009) were found 
between the MISCI and FIQR item on memory problems (r = −.74) and the FSDC- item on cognitive symptoms 
(r = −.69) suggesting good evidence of convergent validity of the MISCI. Moderate correlations were also found 
between MISCI and instruments measuring FM impact (as reported by FIQR; r = −.60), fibromyalginess (FSDC; 
r = −.45), anxiety (HADS- A; r = −.59), depression (HADS- D; r = −.62), perceived stress (PSS; r = −.62), and pain cata-
strophizing (PCS- Total; r = −.58). See Table 3 for more details. A significant correlation between MISCI scores and 
years with FM was also found (r = −.22, p = .03).
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Significant (p < .05) zero- order correlations between brain structure volumes and MISCI scores were 
found with rs ranging from .30 to .46 (i.e., left anterior cingulate cortex [lACC], left middle cingulate cortex 
[lMCC], left lateral orbitofrontal gyrus, left medial orbitofrontal gryus, left inferior orbitofrontal gyrus, right 
posterior cingulate, left superior temporal gryus, and right superior temporal gyrus). When controlling for 
age, years with FM, and total brain volume, only lACC and lMCC were significantly associated with MISCI 
scores (r = .30, p = .04, and r = .38, p = .009, respectively). See Figure 1 for more details regarding these 
areas. No significant associations were observed regarding MISCI scores and other cortical and subcortical 
volumes.
3.4 | Known- groups validity
Table 4 displays the MISCI mean scores for subsamples of patients with FM, with or without Major Depressive 
Disorder comorbid diagnosis, and the comparative sample of patients without FM reporting residual depressive 
symptomatology (i.e., mild depression severity according to PHQ- 9 scores [Mean = 9.03, SD = 6.71]; Kroenke & 
Spitzer, 2002). Univariate ANOVA showed significant between- group differences (F[2,162] = 17.35; p < .001) with 
posthoc analyses indicating worse perceived cognitive performance (i.e., lower MISCI scores) in the FM with 
depression group compared to FM without depression (p < .001; d = .74) and to patients without FM and with 
TABLE  2  Item Content, Mean (M), Standard Deviation (SD), Factor Loadings of the MISCI Items in the FM 
sample (λ of Model 1 and Model 2—respecification of model 1 with correlated error terms on the negatively 
phrased items, −), corrected item- total correlation (rtot), and Cronbach’s α if item deleted
MISCI items M (SD) λ Model 1 λ Model 2 rtot
Cronbach’s α if 
item deleted
1. I have been able to think clearly 
without extra effort
3.14 (1.07) .62 .64 .57 .91
2. My mind has been as sharp as 
usual
2.80 (1.12) .66 .68 .62 .90
3. I have been able to remember 
things as easily as usual without 
extra effort
2.82 (1.06) .77 .81 .72 .90
4. I have been able to learn new 
things easily, like telephone 
numbers or instructions.
2.57 (1.18) .73 .75 .67 .90
5. My ability to concentrate has 
been good.
2.62 (1.14) .85 .87 .78 .89
6. I have been able to pay attention 
and keep track of what I was doing 
without extra effort.
2.79 (1.07) .85 .85 .79 .89
7. I have had trouble shifting back 
and forth between different 
activities that require thinking
3.14 (1.01) .63 .56 .63 .90
8. I had trouble planning out the 
steps of a task
2.57 (1.09) .63 .54 .63 .90
9. I have had to work harder than 
usual to express myself clearly
2.73 (1.20) .64 .53 .66 .90
10. I have had trouble finding the 
right word(s) to express myself
2.96 (1.15) .67 .58 .67 .90
MISCI, Multidimensional Inventory of Subjective Cognitive Impairment.
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Residual Depressive Symptomatology (RDS group) (p < .001; d = −1.09) with medium and large effect sizes, re-
spectively. The FM sample without depression also showed lower MISCI scores compared to the RDS group 
(p = .02; d = −.45).
F IGURE  1  (a) Sagittal (left) and 3D (right) views of the brain depicting the location of the left anterior 
cingulate (red) and the left middle cingulate (green) cortices. (b) Scatter plots depicting the relationship between 
MISCI (Multidimensional Inventory of Subjective Cognitive Impairment) scores and left anterior cingulate (left) 
and left middle cingulate (right) volumes
TABLE  4 Known- groups validity of the MISCI: FM without Major Depressive Disorder (MDD) vs. FM with 
MDD vs. Sample with Residual Depressive Symptoms (RDS)
FM total 
(n = 120)
FM (1) 
(n = 64)
FM + MDD (2) 
(n = 56)
RDS (3) 
(n = 45) ANOVA
T- test 
comparisons Cohen’s d
MISCI  
(M, SD)
29.35 
(8.24)
32.03 
(7.10)
26.29 (8.43) 35.53 
(8.50)
F(2,162) = 17.35
p < .001
1 > 2**
1 < 3*
2 < 3**
.74 
−.45 
−1.09
MISCI, Multidimensional Inventory of Subjective Cognitive Impairment.
*p < .05; **p < .001.
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3.5 | Sensitivity to change
Greater changes in MISCI scores were observed in MBSR group (F[1,57] = 10.92; p = .002; ηp
2 = .16) as suggested by 
main and posthoc analyses, with effect sizes suggesting a large effect of MBSR on MISCI scores (d = .98). Similarly, 
an effect of treatment on FIQR scores was also observed (F[1,54] = 4.70; p = .03) in the MBSR group. Results are 
shown in Table 5.
3.6 | FM- inherent contributors to fibrofog
After controlling for years with FM (the only confounding variable significantly related to MISCI scores), hierar-
chical regression analysis was highly significant (p < .001) with Depressive symptoms, Anxiety symptoms, and 
Balance problems from the FIQR accounting for 43.6% of MISCI variance (with standardized β = −.21 [p = .049], β= 
−.21 [p = .036] and β= −.28 [p = .018], respectively). In this regard, higher scores in these three predictors were re-
lated to worse perceived cognitive functioning (i.e., lower MISCI scores). Pain, energy/fatigue, sleep quality, stiff-
ness, tenderness to touch, and hypersensitivity to external stimuli were not significant predictors of MISCI scores 
in the final model (all p > .05). Other confounding variables entered in the first step such as age, gender, years of 
schooling, and use of psychotropic drugs (i.e., narcotic analgesics, benzodiazepines, antidepressants, hypnotics, 
anti- epileptics) were not significant predictors of MISCI scores (all p > .05). Regarding psychotropic medication 
(not reported in Table 1): 25.8% (n = 31) of the FM sample were under treatment with narcotics, 44.2% (n = 53) 
with benzodiazepines, 36.7% (n = 44) with antidepressants, 3.3% (n = 4) with hypnotics, and 13.3% (n = 16) with 
antiepileptics. The mean number of psychotropic medications was 1.23 (SD = 1.24) and 38.3% of the sample 
(n = 46) did not take any.
Additionally, a linear regression model (enter method) was computed including the three significant predictors 
only (i.e., anxiety, depressive symptoms, and balance difficulties); this model yielded a slightly lower percentage 
of total explained variance (37.6%) with the three predictors remaining significant. See Table 6 for more detailed 
information.
4  | DISCUSSION
Despite the serious impact of perceived dyscognition on quality of life and functionality in those with FM, this 
construct is not usually assessed in clinical research and is not typically a focus of clinical care. Bearing in mind the 
broad range of symptoms that require assessment in FM, measures that are reliable, valid, and brief yet sufficiently 
comprehensive are greatly needed. The psychometric properties of the MISCI, which was designed specifically 
to assess the broad range of cognitive problems that are common in FM, have only been published in English. 
TABLE  5 Change in the MISCI and FIQR after the MBSR intervention
MBSR (n = 37) TAU (n = 22)
Pre Post p d Pre Post p d r- m ANOVA ηp2
MISCI 30.22 
(7.13)
39.08 
(9.09)
<.001 .98 27.95 
(9.51)
29.32 
(11.40)
n.s. .20 F(1,57) = 10.92; 
p = .002
.16
FIQR 61.81 
(18.79)
48.10 
(18.69)
<.001 .74 56.80 
(22.87)
53.14 
(21.85)
n.s. .28 F(1,54) = 4.70; 
p = .03
.08
Changes in FIQR scores were also provided to facilitate clinical interpretation of the results. FIQR, Fibromyalgia Impact 
Questionnaire- Revised; FM, Fibromyalgia; MBSR, Mindfulness- Based Stress Reduction Program; MISCI, Multidimensional 
Inventory of Subjective Cognitive Impairment; TAU, Treatment- as- usual.
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Although items from the MISCI were translated into Spanish by Eremenco et al. (2005), the psychometric proper-
ties of the Spanish adaptation of the MISCI have not previously been published. The present work presents the 
psychometric properties of the Spanish version of the MISCI for the first time and expands its potential applica-
tion to Spanish- speaking individuals.
The MISCI (Kratz et al., 2015) comprises five domains (with two items each) covering common symptoms of 
fibrofog (i.e., memory, verbal language ability, general mental clarity, attention/concentration, and executive func-
tioning). Since MISCI was not devised to evaluate each of these distinct domains but to provide a single compre-
hensive measure on subjective cognitive dysfunction idiosyncratic to FM (Kratz et al., 2015), the CFA conducted 
with the Spanish version of the MISCI aimed to test the unidimensionality of the MISCI. In this regard, adequate 
fit indexes, especially when controlling for method effects and high factor loadings (all λ > .50), were obtained, 
confirming the unidimensionality of the MISCI. Since a better fit was obtained after controlling for method effects, 
future versions of the MISCI may consider not using items with reverse wording (Van Sonderen, Sanderman, & 
Coyne, 2013). In common with the English version, excellent internal consistency was observed in our study 
(α = .91). Test–retest reliability of the MISCI was evaluated for the first time, showing very good temporal stability 
over time (ICC = .88), even more so when considering the long period between test and retest (i.e., 2 months). 
No significant changes in either FIQR or MISCI scores were reported in the TAU group (6.4%, d = .28, p > .05, 
and 4.9%, d = .20, p > .05, respectively), thus ensuring that the test–retest reliability of the MISCI was evaluated 
only in a subset of patients in whom the variable measured (i.e., MISCI scores) has not changed. The sensitivity 
of the MISCI to change was also tested by evaluating pre–post changes after a MBSR program in comparison to 
treatment- as- usual. We corroborated, by means of pre–post changes in FIQR scores (main outcome measure), 
≥20% that MBSR was clinically effective (Bennett, 2005) (MBSR: 22%, d = .74, p < .001). Moreover, even larger 
pre–post improvements (large effect size) in MISCI scores were found (MBSR: 29%, d = .98, p < .001), indicating a 
great impact of MBSR on fibrofog. This finding provides preliminary evidence of the effectiveness of mindfulness- 
based interventions for managing fibrofog symptoms. Previous studies on mindfulness reported some positive 
TABLE  6 Hierarchical regression analysis of MISCI scores (n = 96)
Predictor variables ΔR2 r pr β sr2 t- value
Step 1 .05
Years with FM −.219* −.09 .05 −.969
Step 2 .39
FIQR- Pain- −.323** −.028 −.06 .10 −.499
FIQR- Fatigue −.447** −.137 −.08 .20 −.700
FIQR- Stiffness- −.326** −.077 −.08 .11 −.787
FIQR- Unrefreshing sleep −.382** −.117 −.09 .15 −.896
FIQR- Depression −.469** −.212* −.21 .22 −1.999*
FIQR- Anxiety −.417** −.212* −.21 .17 −2.133*
FIQR- Tenderness to touch −.201* .208 .17 .04 1.500
FIQR- Balance problems −.440** −.325* −.28 .19 −2.409*
FIQR- Environmental 
sensitivity
−.354** −.100 −.09 .12 −.919
Model with all predictors: R = .66, R2= .44, F(10,78) = 6.037, p < .0001.
Model only with three significant* predictors: R = .61, R2= .38, F(3,92) = 18.441, p < .0001.
Note: Zero- order (r) and partial correlations (pr) FIQR items- MISCI controlling for other FM symptoms were calculated. 
FIQR, Fibromyalgia Impact Questionnaire- Revised; FM, Fibromyalgia; MISCI, Multidimensional Inventory of Subjective 
Cognitive Impairment.
*p < .05; **p < .01.
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effects on pain and quality of life (Lauche et al., 2013) but to date none tracked perceived cognitive functioning. 
In fact, there is a striking lack of information regarding the specific effects of pharmacological and nonphar-
macological interventions on objective and, especially, subjective cognitive impairment in FM. Since fibrofog is 
ranked as one of the top contributors to distress in patients with FM, its specific evaluation—as recommended 
by OMERACT- 9 in 2009 (Mease et al., 2009)—should be incorporated and reported in all studies performed in 
the field. The incorporation into clinical and research practice of a reliable, short measure of perceived cognitive 
functioning, such as the MISCI, could contribute to filling this gap.
As expected, we found a significant association between MISCI and FIQR scores, although this relationship 
was slightly lower compared to findings for the English version (Kratz et al., 2015): FIQR- Physical Function r = −.51 
vs. r = −.60; FIQR- Impact r = −.39 vs. r = −.60; FIQR- Symptom r = −.65 vs. r = −.64; and FIQR- Overall score r = −.60 
vs. r = −.70). As legacy measures for fibrofog, we used single items of cognitive complaints from the FIQR and 
FSDC, finding good convergence with MISCI scores (with r = −.74 and r = −.69, respectively). A high correlation 
(r = −.70) between MISCI scores and FIQR cognitive complaints was also reported in the original validation of the 
instrument (Kratz et al., 2015). No significant associations between MISCI scores and sociodemographic variables 
(age, gender, years of schooling) or psychotropic medication use were observed (data not reported; all p > .05). 
However, a significant negative correlation between chronicity (i.e., years living with FM) and MISCI scores was 
found (r = −.22, p < .05) and this association was also significant after controlling for age (data not shown; p < .05), 
suggesting that fibrofog may worsen due to a sustained and cumulative effect of the syndrome over time. These 
results are in contrast with those reported by McCracken and Iverson (2001) in a study with 275 chronic pain pa-
tients where chronicity had no association with perceived dyscognition. Correlations with other relevant clinical 
measures were even higher than with FIQR scores, including HADS- A (anxiety) and HADS- D (depression) sub-
scales (with r of −.59 and −.62, respectively), PSS (perceived stress; r = −.62) and PCS global score (pain catastro-
phizing, r = −.58), confirming a negative association between perceived cognitive function and mood status and 
negative cognitive- affective response to anticipated or actual pain. These findings are in congruence with other 
studies suggesting that fibrofog may be part of a symptom cluster in FM (Williams et al., 2011), meaning that fibro-
fog can increase in intensity with the co- occurrence with other FM symptoms. In this regard, depression, anxiety, 
and distress would not only be related to perceived cognitive disturbances in FM but also to cognitive complaints 
in chronic pain in general (McCracken & Iverson, 2001).
In a recent study incorporating objective measures of cognitive performance, depression together with work-
ing memory, and everyday physical functioning predicted (32% of the total variance) subjective cognitive com-
plaints (Gelonch et al., 2017), indicating that perceived subjective dyscognition may not only be partially related to 
objective cognitive impairments but also to affective symptomatology. Regarding the contributing role of depres-
sion to fibrofog in our results, in the known- groups validity analyses, significant differences in mean MISCI scores 
were found among samples of patients with FM with or without comorbid depression and a clinical comparative 
group without FM suffering residual depressive symptoms. According to these findings, there could be an addi-
tive effect of FM and major depression on perceived cognitive impairment. Interestingly, in our study, depressive 
symptomatology in the group without FM (assessed by means of PHQ- 9) was also significantly correlated with 
MISCI scores despite the small sample size (n = 38; r = −.34; p = .03) giving extra support to the hypothesis re-
garding an independent relationship between depression and perceived cognitive impairment assessed with the 
MISCI. Significant associations between mood status (together with pain, fatigue, and sleep) and fibrofog were 
also reported by Williams et al. (2011) in a sample of 24 patients with FM. Furthermore, in a recent large cross- 
sectional study (n = 681) by McAllister et al. (2016), depression and anxiety were predictors of fibrofog, together 
with pain intensity, autonomic function, and fatigue.
A positive relationship between perceived cognitive deficits and pain catastrophizing was also previously re-
ported in chronic pain samples (Roth et al., 2005). In this regard, higher catastrophizing and pain- related fear/
anxiety can be related to more difficulties in diverting attention away from a painful event, disengaging from a 
pain stimulus, or shifting attention away from pain- related thoughts (Roth et al., 2005). Given that attentional 
     |  17 of 22FELIU- SOLER Et aL.
resources are limited, such increased attentional focus on pain could be at the expense of other competing cog-
nitive demands (Eccleston & Crombez, 1999; Moore, Keogh, & Eccleston, 2013), so impairing cognitive perfor-
mance. Thus, it seems that pain intensity alone may not be sufficient in all cases to produce cognitive deficits and 
that high pain catastrophizing and pain- related anxiety may be key mediating factors in some cases (McCracken 
& Iverson, 2001; Roth et al., 2005).
Regarding the association between fibrofog and neuroimaging data, negative associations between lACC and 
lMCC volumes with MISCI scores were found. Given that ACC and MCC seem to be involved in integrating neg-
ative affect, pain, and cognitive control (Shackman et al., 2011), and that reduced volumes in these areas have 
previously been described in patients with FM (Wallit et al., 2016), our findings provide deeper insight into the 
nature of fibrofog and its overlap with pain and affective processing. At the same time, these findings also provide 
valuable data on the convergent validity of the MISCI with brain- derived markers.
In the hierarchical regression analysis predicting MISCI scores, depression and anxiety FIQR items were signif-
icant predictors (with β = −.21 both) of lower MISCI scores. Surprisingly, in a greater measure than the two afore-
mentioned predictors, a higher beta value (β = −.28) was observed regarding the specific FIQR item on perceived 
problems in balance. The regression model, including all FIQR items controlling for FM chronicity (i.e., years with 
FM) as a first step, predicted 44% of MISCI variance. A more parsimonious model using only the three significant 
predictors from the first model (i.e., depression symptoms, anxiety symptoms, and problems with balance FIQR 
items) accounted for a slightly lower value with 38% of the MISCI variance predicted.
Gender, age, years of schooling, and psychotropic use in the first step of the model, and pain, fatigue, 
stiffness, tenderness to touch, sleep problems, and environmental sensitivity in the second one, although 
that all were significantly related to MISCI scores (with rs ranging between −.21 and −.45), did not contribute 
significantly to the prediction of MISCI scores. In contrast to our findings, McCracken and Iverson (2001), in 
their study with chronic pain patients, found that being more educated, of male gender, and using narcotics or 
antidepressants were related to higher cognitive complaints. In fact, antidepressant use in this study, together 
with pain- related anxiety and depression symptoms, as assessed by the FIQR, predicted 36% of variance in 
MISCI scores. Methodological differences from these other studies may also explain divergence of our results. 
In this regard, FM symptoms (i.e., FIQR items) in our regression analyses were entered as a second step after 
controlling for the effect of chronicity and different measures have been also used (e.g., items vs. complete 
scales). Related to this latter point, it should be pointed out that Williams et al. (2011) used the MASQ to eval-
uate perceived cognitive functions and found significant associations between pain and perceived language 
deficits but not between pain and perceived attention or concentration. Given that MISCI is an amalgamation 
of main fibrofog domains, including language (Kratz et al., 2015), the strength of association between spe-
cific domains of perceived dyscognition and pain (or other FM symptoms) could be “diluted” in our results. 
Regarding unrefreshing sleep and fatigue, we did not find any predictive effect of these FM symptoms on 
MISCI as other authors such as Williams et al. (2011) reported with specific domains of perceived dyscognition 
(i.e., memory). The same explanation of potential dilution of correlations due to the single scoring of the MISCI 
could be applicable.
Regarding the main predictor of fibrofog in our regression analysis, perceived balance problems is one of the 
four new symptoms (i.e., balance, memory, tenderness to touch, and environmental sensitivity) that were added to 
the revised version of the Fibromyalgia Impact Questionnaire (Bennett et al., 2009) and this is reported as one of 
the top 10 most debilitating symptoms in FM, with a prevalence between 45% and 68% (Katz, Ferbert, & Leavitt, 
2007). In the FIQR validation, the item on balance problems provided good discriminant validity between the FM 
group and the other three groups (i.e., healthy controls, a mixed clinical sample with lupus erythematosus/rheu-
matoid arthritis and a sample with Major Depressive Disorder; Bennett et al., 2009) and presented good conver-
gence with the total FIQR score. More recently, Jones and colleagues (Jones, Horak, Winters, Morea, & Bennett, 
2009; Jones, King, Mist, Bennett, & Horak, 2011), evidenced both impaired objective and subjective balance and 
postural functionality in patients with FM.
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Balance control is a complex task which involves a quick and dynamic integration of multiple sensory, motor, 
and cognitive inputs to execute the adequate neuromuscular response needed to maintain balance, requiring 
executive function and attention as well as judgment of external and internal cues (Segev- Jacubovski et al., 2011). 
Impairments in balance and more falls are frequent among the elderly population, especially among patients with 
common neurological diseases (Segev- Jacubovski et al., 2011). In this regard, in the most recent study by Jones 
et al. on this subject (2011), postural stability was predicted by perceived cognitive impairment (assessed with the 
MASQ), together with FIQR scores and body- mass index. Interestingly, Jones et al. (2009) observed a significant 
slowing of walking in patients with FM when dividing attention to a secondary cognitive task, which may be 
suggestive of increased attentional resources devoted to balance and gait control, which are usually regulated au-
tomatically. This lost automatism may also be due to impaired functioning of central, sensory, and/or musculoskel-
etal systems in FM. Performance in dual motor- cognitive tasks is better in younger compared to older individuals 
(Hollman, Kovash, Kubik, & Linbo, 2007), so patients with FM would display a similar pattern to that which occurs 
with aging. In this regard, premature aging has been described in patients with FM and chronic pain (Hassett, 
Clauw, & Williams, 2015) with mounting neuropsychological (Park et al., 2001), neuroimaging (Kuchinad et al., 
2007), and even cellular evidence (Hassett et al., 2012). Thus, reported problems in balance and cognitive function 
may both be related to this premature aging process. Given the significant and moderate association between 
subjective cognitive dysfunction and problems in balance, future studies testing multicomponent treatments for 
fibrofog might also explore the potential benefit of including a module of training balance and postural control.
4.1 | Limitations
This study has some issues that deserve a comment to adequately interpret the scope of the findings. First, 
because the study was conducted in a single hospital and with a relatively small—even though more than suf-
ficient for the analyses conducted—and homogenous sample, the generalizability to patients with different 
sociodemographic or clinical characteristics needs to be determined by future research. Secondly, standard-
ized objective measures of cognitive performance were not used to assess neurofunctional impairment. This 
is not necessarily a limitation in psychometric studies of a patient- reported measure of perceived cognitive 
functioning. In any case, discrepancies between reports from patients with FMS and neuropsychological test-
ing have been described (e.g., Kravitz & Katz, 2015; Walitt et al., 2016). Finally, although a gold standard 
self- reported measure of perceived cognitive dysfunction in fibromyalgia is not available, the present study 
did not include other validated self- report questionnaires—such as the MASQ (Seidenberg et al., 1994) or the 
Mental Clutter Scale (Leavitt & Katz, 2011)—to at least partially assess this construct. Nevertheless, two FIQR 
and FSDC items measuring perceived cognitive dysfunction were used to evaluate the convergent construct 
validity of the MISCI.
In conclusion, the Spanish version of the MISCI demonstrated good to excellent psychometric properties. 
The fact that the MISCI is very brief (i.e., only 10 items), while providing information about a range of perceived 
cognitive problems commonly reported by patients with FM, confirms its potential usefulness to FM researchers 
and clinicians. The MISCI showed a one- factor structure and excellent psychometric properties including inter-
nal consistency, test–retest reliability, and high convergence with cognitive- specific items from FIQR and FSDC, 
severity of FM, depression, anxiety, stress, and pain catastrophizing, suggesting a positive association between 
global severity in this disease and fibrofog. Interestingly, significant correlations between MISCI scores and gray 
matter volumes of pain- related brain areas (i.e., ACC and MCC) have been reported. Significantly different scores 
in MISCI were also found when comparing samples with FM with or without comorbid depression and the clinical 
sample without FM, suggesting an additive effect of FM, and major depression on fibrofog intensity. We also 
found significant and large improvements in perceived dyscognition after an MBSR program, indicating at the 
same time that MISCI displays good sensitivity to change. Although we could not establish causal relationships in 
our study, we found strong correlations between anxiety, depression, and perceived balance problems with MISCI 
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scores, and in hierarchical regression model these three variables were the main predictors of MISCI (over pain 
intensity, stiffness, tenderness to touch, fatigue, environmental sensitivity, or impaired sleep) with a predicted 
variance around 40%.
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